This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
CVS Health Retail Prescription Volume Grows Despite LTC Woes
by Zacks Equity Research
CVS Health's (CVS) consumer centric digital strategy has become even more relevant now.
Cardiovascular Systems Rides on Launches Amid Coronavirus Woes
by Zacks Equity Research
Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.
Boston Scientific Launches DBS System in Europe Post Approval
by Zacks Equity Research
Boston Scientific (BSX) aims to optimize therapy outcomes via the fourth-generation Vercise Genus DBS System's post-regulatory clearance in Europe.
Here's Why You Should Invest in AMN Healthcare (AMN) Stock
by Zacks Equity Research
AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP.
Varian (VAR) Expands Presence With Germany's Ethos Order
by Zacks Equity Research
Varian's (VAR) Ethos therapy is being adopted in Germany, thus expanding the company's geographic footprint.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
Medtronic Receives FDA's Go Ahead for EFS Study on TTVR
by Zacks Equity Research
Medtronic (MDT) begins the FDA-approved EFS of Intrepid TTVR system following the receipt of the Breakthrough Device Designation from the regulatory authority.
National Vision Banks on Contact Lens Sales Amid Coronavirus Woes
by Zacks Equity Research
National Vision (EYE) sales bear the impact of unfavorable timing of unearned revenues.
Here's Why You Should Hold on to Medtronic Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on robust segmental growth and strong ventilators sales.
Here's Why You Should Retain AmerisourceBergen Stock Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches. However, stiff competition remains a woe.
Cerner (CERN) Inks Deal With Finland Regional Leadership
by Zacks Equity Research
Cerner (CERN) collaborates with Finland regional leadership to help bring integrated health and care.
CHDN, AMC, FMS, OMI and TMO as Zacks Bull and Bear of the Day
by Zacks Equity Research
CHDN, AMC, FMS, OMI and TMO as Zacks Bull and Bear of the Day
Varian Expands Access to Advanced Cancer Treatment With Ethos
by Zacks Equity Research
Varian's (VAR) Ethos Therapy used by Goshen Center for Cancer Care marks the expansion access to personalized cancer care.
Coronavirus Test Makers With Scope to Maximize Investor Benefits
by Urmimala Biswas
The surge in new coronavirus infections broadens the scope for antigen and antibody tests.
Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement
by Zacks Equity Research
Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $419.73, marking a +0.34% move from the previous day.
Henry Schein Partners MouthWatch to Grow in Teledentistry
by Zacks Equity Research
Henry Schien's (HSIC) customer base is likely to benefit from the Teledent platform.
QIAGEN, Ellume Extend Alliance for COVID-19 Antigen Test
by Zacks Equity Research
QIAGEN (QGEN) extends partnership with Ellume to offer the second COVID-19 test utilizing the latter's technology and strengthening its own COVID-19-testing portfolio.
3 MedTech Outperformers to Grab Amid Coronavirus Pandemic
by Trina Mukherjee
Let's grab these three stocks that have shown tremendous promise amid the coronavirus pandemic.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Abbott Banks on EPD, Nutrition Growth to Beat Coronavirus Woes
by Zacks Equity Research
Abbott (ABT) expects to register strong growth for the second half of 2020 within established pharmaceuticals (EPD).
HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q2.
PRA Health (PRAH) Inks Deal With Leukemia & Lymphoma Society
by Zacks Equity Research
PRA Health (PRAH) partners with LLS to bring new treatments for children with relapsed acute leukemia.
Bruker Banks on Strategic Innovation Amid Coronavirus Crisis
by Zacks Equity Research
At Bruker's (BRKR) Germany campus, the company currently offers a pilot COVID-19 at work testing program for its factory workforce.
Henry Schein (HSIC) Enters Into New Dental Deal With Zyris
by Zacks Equity Research
Henry Schien (HSIC) is set to be the exclusive distributor of Zyris products like Isolite 3, Isovac 2, Isodry and the company's patented single-use Mouthpieces.